Loading...
Loading...
ASMB| Name | Value |
|---|---|
| Revenues | 6.8M |
| Cost of Revenue | 0.0M |
| Gross Profit | 6.8M |
| Operating Expense | 17.8M |
| Operating I/L | -11.0M |
| Other Income/Expense | 1.3M |
| Interest Income | 1.3M |
| Pretax | -9.6M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -9.6M |
Assembly Biosciences, Inc. is a clinical-stage biotechnology company focused on developing therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its lead product candidate, Vebicorvir, has completed Phase 2 clinical trials for chronic HBV infection. The company is also developing ABI-H3733, which has completed Phase 1a clinical study, and ABI-4334, currently in pre-clinical trials for HBV treatment. Assembly Biosciences has collaboration agreements with BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. to evaluate a triple combination treatment for chronic hepatitis B virus infection. Additionally, it has strategic license agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC.
